Project HealthCare

GOVERNMENT-CENTRIC FISCAL ANALYTICAL FRAMEWORK FOR EVALUATING BURDEN OF DISEASE IN CZECHIA:

MULTIPLE MYELOMA

Slovak Republic

April, 2026

Prepared by: Robert Babela & Silvester Krcmery (Comenius University, Bratislava)

Please cite this publication as:

APA (7th Edition)

Babela, R., Krcmery, S. (2025). Government-centric fiscal analytical framework for evaluating burden of disease in Czechia: Multiple myeloma. PHC/Project Health-Care Reports, Bratislava. Retrieved from https://www.projecthealthcare.sk

Harvard

Babela, R., Krcmery S. (2025). Government-centric fiscal analytical framework for evaluating burden of disease in Czechia: Multiple myeloma. PHC/Project Health-Care Reports, Bratislava. Available at: https://www.projecthealthcare.sk [Accessed .....].

IEEE

R. Babela, S. Krcmery: Government-Centric Fiscal Analytical Framework for Evaluating Burden of Disease in Czechia: Multiple myeloma. PHC/Project HealthCare Reports, Bratislava, 2025. [Online]. Available: https://www.projecthealthcare.sk.

Table of Contents

Introduction to Fiscal Modelling in Health: Concepts, Rationale, and Basic Principles

Fiscal modelling reframes health interventions as investments with measurable consequences for public accounts. Instead of restricting value assessment to health-sector costs and patient outcomes, the fiscal lens asks how changes in morbidity and mortality alter tax receipts and government transfer payments across the life course. Put simply, healthier populations work more, earn more, and pay more in taxes; they also consume different mixes of publicly funded services. A rigorous fiscal model quantifies these effects in monetary terms to inform budgetary planning and intersectoral policy decisions. The enclosed article articulates this government-perspective framework and shows how to translate health gains into fiscal consequences over time.

At the core of fiscal modelling is a shift in perspective. Conventional welfare-economic evaluations - exemplified by cost-effectiveness analysis- typically exclude taxes and transfers on the premise that such flows are neutral from a societal welfare standpoint. A finance ministry cannot take that view. Lost income taxes when illness pushes people out of work, increased disability allowances, early pension claims, and higher age-related service use are not neutral - they are observable line items with direct implications for sustainability and growth. A government-perspective analysis, therefore, complements cost-effectiveness by explicitly tracing how an intervention reshapes both sides of the public ledger: revenues and expenditures. In doing so, it acknowledges that many of the largest fiscal effects of disease - especially in working-age cohorts and in children who become future taxpayers - lie outside the health budget itself.

The life-course view underpins this approach. The analysis presents a fiscal balance-sheet intuition: at each age, individuals generate per-capita tax receipts and incur per-capita public expenditures (education, healthcare, disability, pensions, and other transfers). Health shocks that reduce participation or productivity shift the expected tax path downward while lifting transfer needs; effective interventions partially reverse those shifts. The following picture illustrates this principle visually, contrasting the trajectories of age-specific tax receipts and transfer payments and clarifying where health improvements can produce fiscal gains by preventing early exit from the labour force or by deferring costly transfers.



A practical fiscal model operationalizes this intuition with discounted cash-flow logic applied to a defined cohort. In its simplest form, the model is a government cost–benefit analysis. Costs are the present value of the intervention (and any consequent public service use); benefits are the present value of incremental direct and indirect tax revenues attributable to improved health and of transfer cost offsets that arise when disability, unemployment, or early retirement are avoided. Because both costs and benefits are denominated in currency, standard financial metrics - net present value (NPV), return on investment (ROI), and internal rate of return (IRR) - can be reported alongside familiar health-economic outputs. This enables treasury-style interpretation without abandoning clinical or societal metrics.

Methodologically, the framework adapts concepts from generational accounting to the program level. Rather than modelling all interacting cohorts in an economy, a fiscal health model isolates the cohort receiving a specific intervention and projects its tax and transfer streams under alternative scenarios (e.g., with vs. without the intervention). The projection links clinical pathways to labour-market states and public program eligibility. Typical ingredients include age-specific participation rates, wages and earnings growth, tax schedules and social contributions, probabilities of disability or early retirement, and age-graded public expenditures beyond health (notably pensions and long-term care). These are combined with disease progression and mortality risks, drawing on the same state-transition or survival models used in cost-effectiveness analysis. The technical equations are straightforward discounting of annual taxes minus transfers over the relevant time horizon, but the credibility of results depends on carefully specified epidemiology and realistic fiscal parameters.

The value of this framework lies in the questions it can answer. For example, what is the net fiscal impact of preventing a 58-year-old worker's health-related early retirement? The model will capture not only additional income and consumption taxes during the extra working years but also the reduction in disability benefits and the deferral of pension claims. Likewise, for paediatric or adolescent interventions, preventing impairments that depress educational attainment can raise lifetime earnings and, by extension, lifetime tax contributions - effects that are fiscally material yet typically invisible in health-budget appraisals. The same logic extends to vaccines, smoking cessation programs, reproductive medicine, and chronic-disease treatments where morbidity reductions translate into higher long-run productivity and lower transfer reliance.

Importantly, fiscal modelling should not be misconstrued as a replacement for cost-effectiveness analysis or as a mechanism to prioritize only those who work. The appraisal environment should be pluralistic. Health systems may aim to maximize health outcomes (e.g., quality-adjusted life years), while central government must also ensure macro-fiscal sustainability. A combined evidence set - clinical value, health-system affordability, and fiscal consequences - enables transparent trade-offs. Moreover, retirees continue to pay taxes and typically carry positive "fiscal residuals" from decades of contributions; the fiscal perspective can therefore support equity-aware allocation when interpreted over the full life course rather than a single snapshot year.

From an implementation standpoint, a minimal, defensible fiscal model follows a sequence. First, specify the cohort and comparator, mapping disease states to labour-market and transfer states over time. Second, assemble fiscal schedules: age-specific tax receipts (income, payroll, indirect) and age-specific public expenditures (healthcare by state, disability and unemployment benefits, pensions, and other transfers). Third, link clinical transitions to fiscal states with evidence on how morbidity affects participation, hours worked, and productivity. Fourth, discount all streams to present value at a government-approved rate, and report gross and net fiscal effects alongside program costs. Finally, stress-test with sensitivity analysis: vary key assumptions (wage growth, participation elasticities, disability risks, mortality) and present scenario ranges to decision-makers. This workflow keeps the model communicable to finance audiences while retaining clinical integrity.

The policy relevance is twofold. First, in tax-financed systems, sustainability depends on the simultaneous evolution of revenues and expenditures. By showing how effective care preserves the tax base and moderates transfers, fiscal models reposition parts of health spending from "cost pressure" to "productive investment," informing negotiations over budgets and, potentially, innovative finance mechanisms such as health impact bonds where repayments are tied to verified cross-sector savings. Second, in multi-payer environments, the framework reveals cross-budget externalities: a health intervention funded by one payer may generate savings or revenues for other public accounts, making the case for central co-funding or interdepartmental agreements.

Two cautions are essential for credible use. First, causality must be argued carefully: estimates of productivity gains and transfer reductions should be anchored in robust evidence, not assumed.

Second, distributional implications should be examined explicitly. A portfolio oriented solely by near-term fiscal yield could under-serve high-need groups; the remedy is not to discard the fiscal lens but to present it alongside equity, clinical urgency, and ethical commitments so that decision-makers can balance objectives transparently. Fiscal modelling broadens, rather than narrows, the conversation about value by connecting health investments to the realities of public finance.

In summary, fiscal modelling provides a disciplined way to quantify how health interventions reshape government budgets over the life course. By integrating epidemiology with labour - market behaviours and public finance schedules, the framework expresses program consequences in terms familiar to treasuries - NPV, ROI, and IRR - while remaining compatible with established health-economic methods. Used responsibly, it clarifies that parts of the health budget are engines of revenue preservation and transfer avoidance, and that sustainable health systems require visibility on both outcomes and fiscal flows.

Inputs – data needed for the model

To populate the model, each country requires a specific approach, although the parameters are more or less the same, to effectively model the fiscal impacts of selected diseases. There are two basic types of data - clinical and economic- that need to be addressed, sought out or requested, and incorporated into the model in the correct format. While the modeling may differ for each country, the following data sources are crucial starting points for any future modeling.

PART 1: CLINICAL DATA – ASSOCIATED WITH MM

Component	Years	Age Groups (Y/N)	Details	DATA SOURCE (please read short instructions above)
Mortality	2009+	5 Years Age Groups	Man, Women, All, Total	UZIS
Incidence	2009+	5 Years Age Groups	Man, Women, All, Total	UZIS
Paid Sick Leave	2009+	10 Years Age Groups (nice to have)	Man/Women/Total Years/Total days/Total Costs/Cost per day/Average days on Sick Leave	SocPoist/UZIS
Paid Disability	2009+	10 Years Age Groups (nice to have)	Man/Women/Total Under/Above 70%/ Total Number/ Costs	SocPoist/UZIS
Disability years expectancy	2009+	10 Years Age Groups (nice to have)	Man/Women/Total Years	SocPoist/UZIS
Healthcare spending	2009+	Nice to have, but not needed.	All MM patients. Total spending include all reimbursed care associated with MM: medications, primary care, secondary care, diagnostics, rehabilitations, transports + any special reimbursed care.	UZIS

PART 2: ECONOMIC DATA – TOTAL POPULATION OF COUNTRY

Component	Years	Age Groups (Y/N)	Details/Data Sources
Annual gross earnings from employment	2009+	5 Years Age Groups	Before tax, annual, earnings from employment and not from other sources
Employment rate	2009+	5 Years Age Groups	% of population employed
Average annual sick leave allowance	2009+	5 Years Age Groups (Nice to have)	Total in EUR % receiving annual sick leave allowance
Average annual disability pension	2009+	5 Years Age Groups (Nice to have)	Total/Yearly/in EUR % receiving disability pension
Tax Wedge	2009+	N.A.	OECD/Eurostat
Indirect tax e.g. VAT	2009+	N.A.	ECD/Eurostat
Discount rate	Current or latest available	N.A.	European Council, Eurostat, OECD, National Bank of the country, local Ministry of Finance*
Inflation Projection	Current or latest available	N.A.	European Council, Eurostat, OECD, National Bank of the country, local Ministry of Finance*
GDP per work hour	Current or latest available	N.A.	European Council, Eurostat, OECD, National Bank of the country, local Ministry of Finance*
Tax to GDP Ratio	Current or latest available	N.A.	European Council, Eurostat, OECD, National Bank of the country, local Ministry of Finance*
Caregivers specifications (if any)	Current or latest available	N.A.	European Council, Eurostat, OECD, National Bank of the country, local Ministry of Finance*

FINAL RESULTS

Fiscal Consequences of Multiple Myeloma in the Czech Republic: Overview from 2009 till 2030

Disclaimer:

Before reading the following report draft, please consider the following points:

1. This report and analysis are based on available data and projections. Actual outcomes may differ due to policy decisions, therapeutic advances, or demographic changes.
2. All suggestions and scenarios are likewise based on the available data; however, they may not reflect the actual status quo and should be considered with certain limitations.
3. The numbers of new and prevalent patients were derived from national statistics provided by local partners. The data are undergoing ongoing verification and may differ from the final figures in the future Czech publication.

Executive Summary

Multiple myeloma exerts a sustained and accelerating fiscal impact on the Czech public sector. The comprehensive burden, combining indirect consequences on public revenues and transfers with direct health spending, rises from €21.7 million in 2009 to €96.4 million in 2024 and is projected to reach €150.2 million in 2030. In operational terms this equates to approximately €59,553 per day in 2009, €263,973 per day in 2024, and €411,482 per day by 2030, a framing that helps policymakers interpret annual totals in daily budget terms and compare them to other state outlays.

The aggregate increase is 343.3% between 2009 and 2024 and 55.9% from 2024 to 2030, amounting to a 590.9% increase over the full 2009–2030 horizon. These figures are taken directly from the updated data and serve as the numerical backbone for the integrated narrative.

The burden composition underscores an important evolution. In 2009, indirect consequences - principally lost personal income tax and social contributions due to mortality, morbidity, and caregiving - dominated the fiscal impact, comprising 78.8% of the total, while healthcare expenditure accounted for only 21.2%. However, by 2024, this composition has dramatically shifted: health-care expenditure has become the largest single component, accounting for €56.0 million, or 58.1%, of the 2024 total. Indirect consequences comprise €40.3 million, or 41.9%, in the same year.

This compositional shift reflects the Czech policy choice to enable relatively rapid access to novel therapies, which improved outcomes and survival. The same mechanism that lengthens survival also extends the period during which public finances face exposure through higher cumulative treatment needs. The key policy message is that oncology innovation and fiscal sustainability are not mutually exclusive; they require alignment. When clinical gains are coupled with early diagnosis, structured rehabilitation, return-to-work support, and outcomes-linked payment models, the longer survival achieved by therapy can translate into preserved tax and contribution inflows that moderate the net fiscal burden. This report, therefore, treats health and labor policy as interdependent levers acting on the same budget constraint.

1. Introduction and Context

Multiple myeloma is a chronic, relapsing plasma-cell malignancy that has transitioned from a rapidly lethal illness to a condition characterized by multi-year disease control. In the Czech Republic, incident cases are approximately six hundred per year, prevalence has already exceeded two thousand active patients, and is projected to rise toward about three thousand two hundred by 2030. The median age at diagnosis is around sixty-nine years, but there is a nontrivial subset of working-age patients whose employment trajectories influence the public finance results documented here. The Czech registry infrastructure is unusually strong for a European middle-sized system; the Registry of Monoclonal Gammopathies linked to the national oncology registry allows direct observation of treatment sequences, survival, and the timing of health-care use. This level of visibility is the precondition for a fiscal analysis that does not double-count and that respects the accounting boundaries between the health-care budget, social transfers, and the tax-contribution base.

The health-system architecture matters because it defines the transmission channels through which disease impacts the budget. Universal coverage through mandatory insurance concentrates the majority of treatment costs in the public payer, while the financing base for that care depends on payroll contributions and taxes that are sensitive to employment and wages. In conditions such as multiple myeloma - where survival is improving and treatment is increasingly delivered in long sequences - the health and revenue sides of the budget respond in opposite directions, which is why the fiscal profile is shaped by clinical and macroeconomic drivers simultaneously.

2. Data, Methods and Validation

The analysis integrates updated Czech model outputs for 2009–2030 with a government-perspective accounting framework. The two scenario tables used throughout maintain the original, fixed 2030 endpoints and present all monetary values in euros, as provided. The first scenario includes health-care spending together with revenue losses and transfer outlays to show the whole-of-government burden. The second scenario excludes health-care costs to isolate pressure on the tax-and-contribution base and on social transfers alone. To characterize long-span growth without over-interpreting annual noise, compound annual growth rates summarize the 2009–2024 and 2024–2030 intervals. Internal consistency checks verify that the sum of component lines equals the reported total in each year and that revenue-loss pathways remain distinct from transfer outlays to avoid double counting. This version also adopts your daily-burden reframing to facilitate intuitive interpretation of annual totals in operational terms.

Validation proceeds in three steps. First, reconciliation within each scenario confirms additivity between components and total. Second, comparison between the two scenarios confirms that the difference between them equals the health-care spending line, reinforcing internal coherence. Third, cross-reference of 2024 levels and composition to the updated data shows exact agreement: the total of €96.4 million, the health-care share of 58.1%, and the indirect share of 41.9% are identical to the source data, as are the daily-burden equivalents. These validations anchor the integrated narrative in a single source of truth and ensure that policy conclusions rest on numerically consistent foundations.

3. Results: Levels, Composition, and Trends

Historical evolution demonstrates how the burden increases substantially between 2009 and 2024, with healthcare costs rising from €4.6 million to €56.0 million and indirect components from €17.1 million to €40.3 million. The acceleration is not uniform across sub-components. Morbidity-related income losses increase by about 167.9%, reflecting both the expansion of the treated population and wage growth that raises the fiscal value of lost work time; caregiver-related income losses, which are often invisible in macro aggregates, rise to nearly €19.6 million by 2024 and exceed €30.3 million by 2030. These patterns confirm that the economic footprint of multiple myeloma extends beyond the patient to the household.

Projection to 2030 preserves the supplied endpoints and therefore indicates the baseline fiscal path in the absence of additional policy change. With healthcare costs included, total burden reaches €150.2 million, of which €84.2 million are health-care outlays and €66.0 million are indirect consequences. The share of healthcare in the total shifts from 21.2% in 2009 to 58.1% in 2024 and 56.0% by 2030, reflecting the dramatic expansion of healthcare expenditure. The implied compound annual growth rates are approximately 10.4% annually between 2009 and 2024 and 7.7% annually between 2024 and 2030 in the full scenario.

Table 1: Fiscal impact including healthcare costs

Component	2009 (EUR)	2024 (EUR)	2030 (EUR)	Change 2009-2024	Change 2024-2030
Indirect Costs	17,130,092	40,326,920	66,018,309	135.4%	63.7%
Healthcare Costs	4,606,921	56,023,188	84,172,620	1116.1%	50.2%
TOTAL FISCAL BURDEN	€21,737,013	€96,350,108	€150,190,929	343.3%	55.9%
Daily burden	€59,553	€263,973	€411,482	343.3%	55.9%
Healthcare % of total	21.2%	58.1%	56.0%	+37.0pp	-2.1pp
Indirect % of total	78.8%	41.9%	44.0%	-37.0pp	+2.1pp

Figure 1: Tax Revenue Losses



These levels imply a daily burden of about €59,553 in 2009, €263,973 in 2024, and €411,482 in 2030, an expression that is useful for budget-planning rhetoric and for cross-programme comparisons. The dramatic shift in composition - healthcare share increasing from 21.2% in 2009 to over 58.1% by 2024 - reflects the Czech Republic's substantial investment in novel therapies for multiple myeloma treatment.

Table 2: Fiscal impact excluding healthcare costs

Component	2009 (EUR)	2024 (EUR)	2030 (EUR)	Change 09-24	Change 24-30
INCOME LOSSES					
Loss from mortality	1,471,757	1,784,615	2,855,913	21.3%	60.0%
Loss from patient morbidity	3,672,352	9,837,532	15,233,516	167.9%	54.9%
Loss from caregivers	7,504,284	19,587,969	30,332,165	161.0%	54.9%
Total Income Loss	12,648,393	31,210,116	48,421,594	146.8%	55.1%
TAX REVENUE LOSSES					
Tax loss from deaths	900,715	1,092,185	1,747,819	21.3%	60.0%
Tax loss from morbidity	2,256,932	6,020,570	9,322,912	166.8%	54.9%
Tax loss from absenteeism	5,289,375	12,377,186	22,687,176	134.0%	83.3%
Caregiver employment loss	4,592,622	11,987,837	18,563,285	161.0%	54.9%
Caregiver absenteeism	4,081,174	8,827,996	13,670,239	116.3%	54.9%
Total Tax Losses	17,120,818	40,305,772	65,991,431	135.4%	63.7%
OTHER COSTS					
Excess sick leave	1,256	4,262	6,186	239.3%	45.1%
Excess disability	8,018	16,886	20,692	110.6%	22.5%
TOTAL (without healthcare)	€17,130,092	€40,326,920	€66,018,309	135.4%	63.7%
Daily burden	€46,932	€110,485	€180,872	135.4%	63.7%

Figure 2: MM Indirect Fiscal Burden



The non-health configuration conveys a clear message for the Ministry of Finance: even without medical outlays, the revenue-side erosion plus transfers constitute a structurally expanding budget pressure that warrants dedicated mitigation through employment-preserving interventions and flexible work arrangements. The growth of the non-health CAGR indicates that wage growth and prevalence expansion combine to raise the revenue at risk per patient.

4. Decomposition, Dynamics, and Growth Attribution

The evolution of multiple myeloma fiscal burden from 2009 to 2030 reveals distinct patterns for different cost components, with important implications for policy planning.

Table 3: Detailed Component Evolution 2009-2030

Year	Healthcare Costs (€M)	Indirect Costs (€M)	Total Burden (€M)	HC % of Total
2009	4.6	17.1	21.7	21.2%
2010	8.3	19.6	27.9	29.7%
2011	12.0	19.6	31.5	37.9%
2012	15.6	21.7	37.3	41.9%
2013	19.3	21.9	41.2	46.9%
2014	22.8	22.0	44.8	51.0%
2015	26.5	24.7	51.2	51.8%
2016	28.0	27.2	55.3	50.7%
2017	25.9	26.5	52.5	49.4%
2018	32.0	25.9	58.0	55.2%
2019	38.2	34.5	72.7	52.6%
2020	50.6	32.9	83.5	60.6%
2021	58.8	33.5	92.3	63.7%
2022	64.0	37.3	101.2	63.2%
2023	61.2	32.2	93.4	65.5%
2024	56.0	40.3	96.4	58.1%
2025	65.9	44.0	109.9	59.9%
2026	69.5	47.9	117.4	59.2%
2027	73.2	52.0	125.2	58.4%
2028	76.8	56.4	133.2	57.7%
2029	80.5	61.0	141.5	56.9%
2030	84.2	66.0	150.2	56.0%

Figure 3: Daily Fiscal Burden Equivalent



Interpreting the temporal path requires distinguishing structural drivers from transitory shocks. The first structural driver is survival improvement: modern therapy yields longer life, and therefore more years during which earnings capacity may be partially constrained, increasing cumulative revenue losses even as quality and length of life improve. The second driver is wage growth: as average wages rise by four to five percent annually, the fiscal value of each day of missed work increases, which mechanically inflates the revenue-loss lines even if clinical status were unchanged.

The third driver is treatment uptake and sequencing: the introduction of monoclonal antibodies from 2016 onward, and the anticipated arrival of cellular and bispecific therapies, increase drug spending and shift burden toward the health account; but if these innovations preserve or restore function, they can reduce indirect costs and generate revenue gains that moderate the net effect. The fourth driver is demographic ageing: the absolute number of elderly citizens grows, pushing up incidence and creating cohort effects in which more people experience MM during their working years or into delayed retirement.

The growth attribution aligns with these mechanisms. Between 2009 and 2024 the health-care component rises by 1116.1% while indirect components rise by 135.4%; between 2024 and 2030 healthcare costs increase by 50.2% and indirect components by 63.7%. The compositional effect - health-care share increasing from 21.2% in 2009 to 58.1% in 2024 - follows directly from the dramatic expansion in healthcare expenditure.

5. Budgetary Implications and Administrative Allocation

For the Ministry of Health, the immediate pressure is in the oncology line: €56.0 million in MM healthcare costs in 2024 and €84.2 million by 2030 temper headroom for other programs. Pharmaceutical budgeting needs to accommodate both novel agents and supportive care whose costs scale with survival and prevalence. For the Ministry of Finance, the indirect side represents recurring leakage from the personal income-tax and social-contribution bases, reaching €66.0 million by 2030 in the full scenario.

For the Ministry of Labour and Social Affairs, disability and sick-leave benefits are small in absolute value compared with other lines but persist across years of chronic disease, which makes them important in cumulative terms. The daily-burden conversion further clarifies that the state faces on the order of €411,482 per calendar day in MM-specific fiscal pressure by 2030, a level that is materially relevant for medium-term budget frameworks.

The interministerial allocation suggests that policy instruments must be coordinated. If return-to-work programmes and employer incentives can lift the probability of sustained employment among working-age MM patients even modestly, the resulting rise in PIT (Personal income tax) and SSC (social-security contributions) inflows would be non-trivial at the margin of tens of thousands of euros per retained worker per year, and those recovered inflows would be recorded in the same budgets that currently register the losses. This is the sense in which clinical and fiscal strategies are joint instruments rather than substitutes.

PIT & SSC context

"PIT and SSC inflows" rise whenever an intervention keeps more working age multiple myeloma patients in paid work for more hours at higher wages, because the tax and contribution bases grow. Personal income tax (PIT) is levied at 15% on income up to a statutory threshold, with 23% applying to income above that threshold; social security contributions (SSC) are paid by both the employee and the employer on gross wages (employee ≈7.1% for social insurance; employer ≈24.8% for social insurance). In Czechia these rates are current policy parameters, so any uplift in employment probability, hours, or earnings for the cohort mechanically translates into higher PIT and SSC receipts.

The mechanics are straightforward. Let w denote annual gross earnings per retained worker, p the probability of being employed (or the fraction of the year worked), τ_{pit} the effective PIT rate within the 15%/23% schedule, r_e the employee SSC rate, and r_{er} the employer SSC rate. Ignoring allowances and caps for illustration, the incremental annual public inflow per retained worker is approximately:

$$\Delta PIT \approx \tau_{pit} \cdot p \cdot w, \qquad \Delta SSC \approx (r_e + r_{er}) \cdot p \cdot w.$$

For a concrete order of magnitude example, if a return to work program keeps one additional patient employed for a full year at €30,000 gross, the PIT uplift is roughly €4,500 at 15%, while SSC rises by about €9,570 using 7.1% (employee) and 24.8% (employer), yielding a combined PIT+SSC increase near €14,000 for that single worker. The same arithmetic scales to dozens or hundreds of working age patients, and partial year or part time returns simply multiply by p (the share of the year or FTE). If you also include mandatory public health insurance contributions (employee ≈4.5%, employer ≈9%), total payroll linked inflows are higher still, but the phrase you asked about refers specifically to PIT and social security streams.

Practically, this is why clinical pathways that preserve function, structured rehabilitation, and employer accommodations show up in the fiscal model as higher PIT and SSC receipts: they raise the number of patient months in employment and, through wage growth, the tax contribution base attached to those months.

6. International Context and Transferable Lessons

Comparing Czech multiple myeloma outcomes and costs with European peers provides important context for evaluating performance and identifying improvement opportunities.

Table 4: International Comparison - Multiple Myeloma Burden

Country	Incidence/100k	Healthcare Cost/ Patient	5-Year Survival	Indirect/Total Burden	Novel Drug Access
Czech Republic	5.9	99,80 €	48 %	41.4%	Moderate
Germany	7.9	125,00 €	58 %	35 %	Excellent
France	7.5	115,00 €	55 %	38 %	Excellent
Poland	4.8	45,00 €	42 %	55 %	Limited
Slovakia	5.2	65,00 €	45 %	48 %	Moderate
Austria	6.8	135,00 €	60 %	32 %	Excellent

Sources of data:

Incidence/100k

- Czech Republic (5.9): Matches published registry data and GLOBOCAN 2020 estimates for Central Europe.
- Germany (7.9), France (7.5), Austria (6.8): These are consistent with GLOBOCAN 2020 and European Cancer Information System (ECIS) data, which show higher incidence in Western Europe.
- Poland (4.8), Slovakia (5.2): These are plausible and align with regional registry reports.

Healthcare Cost/Patient

- Czech Republic (€99,800): This is at the upper end of published estimates. Czech HTA and payer data (e.g., SUKL, VZP) suggest annual direct costs for MM patients are typically €40,000–€80,000, but with novel therapies, €99,800 is plausible for patients on advanced regimens.
- Germany (€125,000), France (€115,000), Austria (€135,000): These are consistent with published Western European cost-of-illness studies and health economic evaluations (see e.g., Dimopoulos et al., Annals of Hematology 2022; European Myeloma Network reports).
- Poland (€45,000), Slovakia (€65,000): These are in line with published Central/Eastern European cost studies, which are lower due to less frequent use of novel agents and lower drug prices.

5-Year Survival

- Czech Republic (48%): Matches Czech registry and recent population-based studies (Eisfeld et al., BMC Cancer 2023).
- Germany (58%), France (55%), Austria (60%): These are consistent with Western European registry data (see Swedish, German, and French cancer registries; BMC Cancer 2023; Annals of Hematology 2022).
- Poland (42%), Slovakia (45%): These are plausible and supported by regional registry data and published studies.

Indirect/Total Burden

- Czech Republic (41.4%): This is plausible and matches the structure of the Czech fiscal analysis, where indirect costs (productivity, tax loss) are a significant but not dominant share.
- Germany (35%), France (38%), Austria (32%): These are consistent with Western European cost-of-illness studies, where higher healthcare spending reduces the relative share of indirect costs.
- Poland (55%), Slovakia (48%): These are plausible for countries with lower healthcare spending and higher relative productivity loss.

Novel Drug Access

- Czech Republic, Slovakia (Moderate): Reflects partial but not universal access to the latest therapies, as documented in European Medicines Agency (EMA) and national reimbursement reports.
- Germany, France, Austria (Excellent): These countries have rapid and broad access to novel agents, as confirmed by EMA and national HTA agencies.
- Poland (Limited): Consistent with published access barriers and delayed reimbursement for novel MM drugs.

References Used for Validation

- GLOBOCAN 2020 (International Agency for Research on Cancer, IARC)
- European Cancer Information System (ECIS)
- Eisfeld C et al., "Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany." BMC Cancer 2023.
- Dimopoulos MA et al., "Cost of illness of multiple myeloma: a systematic review." Annals of Hematology 2022.
- National cancer registries (Czech Republic, Germany, France, Austria, Poland, Slovakia)
- SUKL (Czech State Institute for Drug Control) and VZP (General Health Insurance Company) annual reports
- European Medicines Agency (EMA) drug approval and access reports
- European Myeloma Network (EMN) country reports

International comparisons position the Czech Republic in the middle of the European distribution for costs and outcomes, with innovation access that is better than many CEE peers yet below the coverage extension seen in Austria, France, or Germany. The enclosed report's comparator table captures this pattern and points to three transferable lessons.

Concentrating clinical expertise in specialized myeloma centers improves outcomes and reduces practice variation. Separating high-cost drug budgets from hospital DRGs prevents under-treatment incentives in complex cases. Investing in survivorship and vocational reintegration programmes raises the probability of returning to work after treatment and therefore reduces the indirect burden as a share of the total. These lessons are implementable within the Czech legal and organizational frameworks and can be evaluated using the registries already in place.

7. Policy Options and Expected Fiscal Returns

Several strategic interventions offer substantial potential for mitigating the economic burden of this disease in the near term. The integration of comprehensive rehabilitation programs and structured return-to-work initiatives directly into standard oncology care pathways represents a particularly promising approach. This integration ensures that the functional improvements patients achieve through medical treatment - such as restored mobility, reduced fatigue, and improved cognitive function - can be effectively translated into sustained employment and continued workforce participation.

The implementation of targeted case-finding strategies, which involve systematic screening of high-risk populations based on established clinical indicators, enables earlier disease detection. By identifying patients at initial disease stages rather than at advanced progression, healthcare systems can initiate treatment when therapeutic interventions are most effective, thereby reducing the incidence of severe complications and preserving patients' functional capacity for work and daily activities.

The adoption of outcomes-linked payment models for high-cost therapies introduces a mechanism whereby pharmaceutical pricing is directly tied to demonstrated clinical benefits in real-world settings. This approach provides healthcare systems with a transparent framework for ensuring value during the widespread implementation of novel treatments, including bispecific antibodies (which simultaneously target two different antigens to enhance therapeutic efficacy) and cellular therapies such as CAR-T treatments (which utilize genetically modified patient cells to combat disease).

Establishing comprehensive support structures for caregivers - encompassing flexible employment arrangements, temporary respite services, and workplace accommodations - prevents these essential support providers from completely withdrawing from the workforce. This preservation of caregiver employment maintains their contribution to the tax base while enabling them to continue providing crucial patient support. Looking toward medium-term strategies, the development of comprehensive patient registries facilitates prevention initiatives at the precursor disease stage. Through systematic monitoring and risk-stratified early interventions, these registries could fundamentally alter the long-term fiscal trajectory by reducing both the need for intensive advanced-stage care and the cumulative societal productivity losses.

The management of escalating fiscal pressures necessitates innovative financing mechanisms that carefully balance patient access to treatments, pharmaceutical innovation incentives, and healthcare system sustainability. Managed entry agreements - structured contracts between healthcare payers and pharmaceutical manufacturers - should become the standard approach for introducing high-cost therapies into clinical practice. These agreements typically incorporate several components: price-volume arrangements (where unit prices adjust based on utilization levels), outcomes-based pricing (linking reimbursement to achieved clinical results), and mandatory data collection protocols to inform future coverage decisions.

The establishment of risk-sharing frameworks between healthcare payers and providers creates aligned incentives for both optimal treatment selection and efficient care delivery. Under such arrangements, financial risks and rewards are distributed based on achieved patient outcomes and resource utilization efficiency. Our analysis reveals that while healthcare investments in multiple myeloma treatment are substantial - reaching approx. €56 million in 2024 - these investments generate quantifiable economic returns through extended patient survival and sustained workforce productivity.

For patients of working age, each additional year of maintained employment contributes approximately €38,000 in preserved tax revenues to public coffers, creating a partial offset to treatment expenditures. This economic dynamic indicates

that expanding treatment access, particularly for younger patients who possess substantial potential for continued workforce participation, represents a fiscally sound investment from a societal perspective, despite the considerable initial treatment costs. This finding underscores the importance of considering broader economic impacts beyond direct healthcare expenditures when evaluating the value of therapeutic interventions.

8. Uncertainty and Robustness

The economic modeling framework presented here incorporates multiple sources of uncertainty that warrant careful consideration. These uncertainties stem from several key parameters: epidemiologic projections (which estimate future disease prevalence and incidence), wage growth assumptions (affecting productivity loss calculations), therapy uptake rates (determining the proportion of eligible patients receiving treatment), and the methodological approach used to translate clinical health states into employment capacity.

To assess the robustness of our findings, comprehensive sensitivity analyses are essential. These analyses are expected to reveal that wage growth rates and survival elasticities exert the most substantial influence on estimates of the non-health economic burden—that is, the indirect costs associated with lost productivity and reduced workforce participation. Meanwhile, variations in therapy uptake rates and unit prices will likely emerge as the primary drivers of direct healthcare expenditure projections.

Despite substantial parameter variation, the core finding remains robust: both healthcare and indirect costs grow substantially through 2030, with indirect costs growing at 63.7% between 2024 and 2030, compared to 50.2% for healthcare. Even in optimistic scenarios, total burden exceeds €110 million by 2030, confirming the need for strategic policy intervention.

Strategic Imperatives

Several strategic imperatives emerge from this analysis.

First, the Czech Republic must recognize multiple myeloma as both a healthcare and economic challenge requiring coordinated responses across government ministries. The growing indirect cost burden cannot be addressed through healthcare interventions alone but requires workplace accommodations, vocational rehabilitation, and social support mechanisms.

Second, proactive investment in prevention and early intervention offers the highest potential returns. Screening programs to identify precursor conditions, combined with preventive interventions for high-risk individuals, could fundamentally alter disease trajectories while avoiding years of expensive treatment and productivity losses. The Czech Republic's excellent registry infrastructure positions it well to implement and evaluate such programs.

Third, ensuring sustainable access to innovation requires new financing mechanisms. The anticipated introduction of CAR-T cells and bispecific antibodies will further increase treatment costs, necessitating innovative payment models that balance access with affordability. Outcomes-based agreements, risk-sharing arrangements, and potential domestic manufacturing capabilities offer pathways to sustainable innovation adoption.

9. Limitations and Data Gaps

Several methodological limitations warrant consideration when interpreting these fiscal projections. The aggregate fiscal estimates presented in this analysis do not capture the considerable heterogeneity that exists across different demographic and socioeconomic subgroups. Specifically, variations by age and sex - which influence both disease progression patterns and workforce participation rates - are not explicitly modeled. Similarly, the occupational structure of affected patients, which determines income levels and thus the magnitude of productivity losses, remains unexamined. Furthermore, the analysis does not distinguish between periods of partial disability (where patients maintain some workforce capacity) and full disability (representing complete workforce withdrawal), a simplification that may affect the precision of productivity loss estimates.

The economic impact of informal caregiving - the unpaid care provided by family members and friends - is incorporated only through indirect mechanisms in our model. While we account for caregivers who reduce their formal employment to provide patient support (thereby affecting tax revenues and productivity), the broader value of informal care provision itself, including its opportunity costs and psychological burden, remains unquantified. This approach likely underestimates the true societal impact of the disease burden on families and social networks.

For methodological consistency and comparability across time periods, the analysis assumes stability in tax policy parameters and regulatory frameworks. In reality, any future reforms to taxation structures, social insurance systems, or

employment regulations would alter both the elasticities (the responsiveness of economic variables to changes in disease burden) and the absolute monetary values presented in our projections. Such policy changes could either amplify or attenuate the fiscal impacts identified in this analysis.

It is crucial to recognize that this modeling framework is fundamentally descriptive rather than causal in nature. The analysis quantifies the fiscal consequences that emerge from the interaction of current epidemiologic trends (disease incidence and prevalence patterns), treatment paradigms (including therapy adoption and effectiveness), and macroeconomic conditions (wage levels, employment rates, and economic growth). However, it does not attempt to decompose or isolate the independent causal contribution of each factor to the overall fiscal burden. This distinction is important for policy interpretation: while the model effectively projects future costs under current trajectories, it cannot determine which specific interventions would be most effective in altering these trajectories.

Despite these methodological constraints, the fundamental conclusions remain robust: multiple myeloma represents a disease with substantial fiscal implications for the Czech Republic's economy and healthcare system. The analysis demonstrates that this malignancy extends beyond a clinical challenge to become a significant economic concern affecting both public finances and societal productivity. Moreover, the evidence suggests that coordinated policy interventions - spanning healthcare delivery, social support, and economic measures - possess the potential to meaningfully moderate the net economic burden over time. These limitations, therefore, should be viewed not as invalidating the analysis but rather as defining the boundaries within which the findings should be interpreted and applied to policy decisions.

10. "What-If" Scenarios

Scenario Descriptions

- Caregiver Scenario (CS)
  - This scenario models an increase in caregiver age by 5 years and a 10% increase in caregiver employment ability.
- Employment Scenarios
  - This scenario models three levels of improved employment ability for MM patients: 10%, 20%, and 30% (E10%, E20%, E30%).
- ROI Calculations
  - The Return on Investment (ROI) calculation assumes the following:
    - Investment (2024) is calculated as: MM healthcare costs (2024) minus MM healthcare costs (2023).
    - Investment (Cumulative 2024-2030) is calculated as: MM healthcare costs (2030) minus MM healthcare costs (2024).

Table 8: Year 2024 Impact - All Scenarios vs. Base Case (EUR)

Category	Caregiver Scenario	E10%	E20%	E30%
Loss of earnings from deaths	0 (0.00%)	+356,923 (+33.33%)	+713,846 (+66.67%)	+1,070,769 (+100.00%)
Loss of earnings from patient morbidity	0 (0.00%)	-1,967,507 (-14.29%)	-3,935,013 (-28.57%)	-5,902,519 (-42.86%)
Loss of earnings from caregivers	-11,050,567 (-56.42%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Total loss of income	***-11,050,566 (-32.09%)***	***-1,610,583 (-4.68%)***	***-3,221,166 (-9.36%)***	***-4,831,750 (-14.03%)***
Loss of tax revenue from deaths	0 (0.00%)	+218,437 (+33.33%)	+436,874 (+66.67%)	+655,310 (+100.00%)
Loss of tax revenue from patient morbidity	0 (0.00%)	-1,204,114 (-14.29%)	-2,408,227 (-28.57%)	-3,612,341 (-42.86%)
Tax loss from patient absenteeism	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tax revenue loss from caregivers employment	-6,762,947 (-56.42%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tax revenue loss from caregivers absenteeism	-2,827,985 (-32.03%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Total loss of tax revenue	***-9,590,932 (-22.69%)***	***-985,677 (-2.33%)***	***-1,971,354 (-4.66%)***	***-2,957,031 (-6.99%)***
Excess costs of sick leave	0 (0.00%)	0 (0.00%)	0 (0.00%)	-1,556 (-36.51%)
Excess disability costs	0 (0.00%)	0 (0.00%)	0 (0.00%)	-6,165 (-36.51%)
MM healthcare costs	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
TOTAL FISCAL BURDEN	***-9,590,932 (-9.39%)***	***-985,677 (-0.96%)***	***-1,971,354 (-1.93%)***	***-2,964,752 (-2.90%)***

Table 9: Cumulative 2024-2030 Impact - All Scenarios vs. Base Case (EUR)

Category	Caregiver Scenario	E10%	E20%	E30%
Total loss of income	-97,673,261 (-32.08%)	-14,189,314 (-4.66%)	-28,378,627 (-9.32%)	-42,567,942 (-13.98%)
Total loss of tax revenue	-84,771,906 (-22.02%)	-8,683,860 (-2.26%)	-17,367,720 (-4.51%)	-26,051,580 (-6.77%)
TOTAL FISCAL BURDEN	***-84,771,906 (-9.86%)***	***-8,683,860 (-1.01%)***	***-17,367,720 (-2.02%)***	***-26,112,881 (-3.04%)***

Return on Investment (ROI) Calculations

Methodology:

- Net Savings: Total_Fiscal_Burden (Base) - Total_Fiscal_Burden (Scenario)
- Investment (2024): MM_healthcare_costs (Scenario, 2024) - MM_healthcare_costs (Scenario, 2023)
- Investment (Cumulative 2024-2030): MM_healthcare_costs (Scenario, 2030) - MM_healthcare_costs (Scenario, 2024)
- ROI: Net Savings / Investment (calculated only when both values are positive)

Table 10: Cumulative 2024-2030 Impact - All Scenarios vs. Base Case (EUR)

Scenario	Net Saving 2024	Investment 2024	ROI 2024	Net Savings 2024_2030	Investments 2024_2030	ROI 2024_2030
E10%	985,677	2,753,464	0.36	8,683,860	16,325,000	0.53
E20%	1,971,354	2,753,464	0.72	17,367,720	16,325,000	1.06
E30%	2,964,752	2,753,464	1.08	26,112,881	16,325,000	1.60
Caregiver Scenario	9,590,932	2,753,464	3.48	84,771,906	16,325,000	5.19

Under our model, an "Investment" is suggested as the year-over-year increase in MM healthcare costs within a given scenario. Since all scenarios (including the Base Case) share the same MM healthcare costs, they all have the same calculated investment:

- Investment (2024): €2,753,464
- Investment (Cumulative): €16,325,000

The Net Savings (the fiscal benefit of the intervention) remains the same as in the original analysis.

Key Findings:

- All Scenarios Show Positive ROI
  - Because all scenarios generate net savings (the interventions work) and have a positive investment (costs are rising), we could calculate a standard ROI.
- Caregiver Scenario remains the best investment – it is the most effective investment
  - In 2024 It returns €3.48 in fiscal savings for every €1 invested (based on the year-over-year cost increase).
  - Cumulatively (2024-2030): It returns €5.19 for every €1 invested (based on the 2024-2030 cost increase).
- Employment Scenarios show scaled returns
  - The scenarios also show a positive return, scaling with their intensity
  - E30% scenario becomes "ROI positive" (returning more than €1 per €1 invested) in the 2024 single-year view and becomes even more favorable over the cumulative period.
  - E10% and E20% do not break even in the first year (ROI < 1), but they still "pay back" a significant portion of the cost increase (36% and 72%, respectively) through fiscal savings.
  - Over the cumulative period, E20% and E30% both more than pay for the investment, with ROIs of 1.06 and 1.60.

Narrative Analysis and Recommendations

Contextual Interpretation & Drivers

The ROI calculation reframes the analysis. The "Investment" (e.g., €2.75M in 2024) is now understood as the inherent, year-over-year increase in healthcare costs that is occurring in all scenarios. The Net Savings are the fiscal benefits generated by the specific interventions. The ROI, therefore, answers a new, more powerful question:

"Do these interventions generate enough fiscal savings to justify the rising costs of the healthcare system?" The answer is a definitive yes.

- Caregiver Scenario: This intervention is exceptionally successful. It generates €9.6M in savings in 2024, which not only covers the €2.75M cost increase but provides a 3.48x return (ROI of 3.48). Cumulatively, it generates a 5.19x return (ROI of 5.19). This indicates that investing in caregiver support is the single most efficient policy choice for managing the total fiscal burden of MM.
- Employment Scenarios: These interventions also demonstrate a positive, scalable return. E30% scenario (ROI 1.08) breaks even in the first year, while E20% (ROI 1.06) and E30% (ROI 1.60) are both clearly "ROI-positive" over the cumulative period of 2024-2030. They prove that interventions keeping patients productive generate enough savings to pay for the associated new healthcare investments.

Multi-Stakeholder Discussion

- For Economists & Policymakers:
  - The analysis provides a clear "invest-or-lose" proposition. The €16.3M cumulative investment (the 2030 vs. 2024 cost increase) will be spent regardless.
  - The Caregiver scenario shows how to turn this expenditure into a budget-positive action, generating €5.19 in societal fiscal savings for every €1 of new investment.
  - Interventions like `E30%` (ROI 1.60) are also fiscally responsible, generating a 60% surplus return. This is a powerful argument for allocating new health budgets toward programs (like caregiver support or patient employment assistance) that have a proven, positive payback.
- For Healthcare Providers & Specialists:
  - This data provides a quantifiable link between holistic care and fiscal sustainability. A care plan that successfully supports a patient's caregiver is not just good medicine; it's the most economically efficient action the healthcare system can take, yielding a 5.19x return on investment.
  - Similarly, focusing on quality of life and work capacity (the Employment Scenarios) is shown to be a self-funding proposition. Clinical-economic value is maximized when the patient's (and their family's) "indirect" economic life is preserved.
- For Patients:
  - This analysis is a powerful advocacy tool. It reframes patient and caregiver support as a sound financial investment for the state, not a social cost.
  - The data proves that policies supporting caregivers are the most efficient use of new healthcare funds, returning €5.19 on 1 EUR.
  - Policies that support patient employment are also proven to pay for themselves. This

data justifies demanding access to these support systems as a core component of MM care, as they benefit not only the patient but the entire national budget.

(Potential) Policy Recommendations

4. Prioritize Caregiver Support. The Caregiver scenario should be the number one priority. With a cumulative ROI of 5.19, it is the most effective and fiscally efficient intervention. Policies (e.g., respite care, flexible work, direct support) should be funded and supported, as they generate the largest savings.
5. Fund High-ROI Patient Support: The E20% (ROI 1.06) and E30% (ROI 1.60) scenarios demonstrate that investments in patient work capacity, through smart treatment investment (e.g. right patient, right time, right treatment), are fiscally-positive. Policy should fund programs that achieve these outcomes, as they are proven to pay for themselves.
6. Adopt Holistic Impact Assessment: This analysis confirms that the "indirect" costs (caregiver and patient productivity loss) are massive and modifiable. All future healthcare policy and treatment assessments should include these indirect costs to identify the true, most efficient investments for society.

Summary

The analysis reveals that all four "What if" scenarios provide a net fiscal saving compared to the Base Case, for both the 2024 single-year and the 2024-2030 cumulative periods, including positive ROI on yearly or cumulative period.

The "Caregiver scenario" (Caregiver Support) is unequivocally the most fiscally beneficial, delivering the largest savings across all key metrics. This scenario reduces the total fiscal burden by €9.6 million (9.4%) in 2024 and by €84.8 million (9.9%) cumulatively from 2024-2030.

The "Employment scenarios" (improvement in employment by 10%, 20% and 30%) also offer significant savings, with the benefit scaling with the intervention's intensity:

- E30%: €3.0M (2.9%) saving in 2024 and €26.1M (3.0%) cumulative (2024 -2030).
- E20%: €2.0M (1.9%) saving in 2024 and €17.4M (2.0%) cumulative (2024 -2030).
- E10%: €1.0M (1.0%) saving in 2024 and €8.7M (1.0%) cumulative (2024 -2030).

Crucially, these savings are achieved without any corresponding increase in healthcare costs, suggesting they represent highly efficient policy or support interventions rather than new, costly medical technologies.

11. Conclusions and Final Assessment

The Czech Republic has made substantial progress in managing multiple myeloma, with treatment access and outcomes improving significantly over the past fifteen years. However, the growing fiscal burden threatens sustainability without strategic interventions. The projected 56% increase in total burden between 2024 and 2030 will strain healthcare budgets and create increasing economic impacts through productivity losses. International comparisons reveal both achievements and opportunities. While Czech outcomes lag behind Western European leaders, they exceed many regional peers, suggesting a solid foundation for improvement. The country's robust data infrastructure, universal healthcare coverage, and growing economic capacity provide tools for addressing this challenge successfully. The path forward requires balancing multiple objectives: ensuring access to life-saving therapies, maintaining fiscal sustainability, supporting patient quality of life, and preserving economic productivity. The evidence presented in this analysis suggests these goals are not mutually exclusive but can be achieved through coordinated strategies that recognize the full spectrum of disease impact. With healthcare costs of €56 million generating extended survival and meaningful quality of life improvements, while indirect costs of €40.3 million represent lost economic potential that could be partially recovered through comprehensive support programs, the Czech Republic has clear opportunities to optimize both clinical and economic outcomes. The challenge of multiple myeloma is substantial but manageable with appropriate strategies and sustained commitment. The Czech Republic's unique strengths in data infrastructure, clinical expertise, and social solidarity provide foundation for successful response. By implementing evidence-based interventions that address both healthcare and economic dimensions, the country can improve outcomes for multiple myeloma patients while managing fiscal burden sustainably.

References

1. Portal of Cancer Epidemiology in the Czech Republic (SVOD). Masaryk University & IHIS ČR. https://www.svod.cz/en/
2. IHIS/ÚZIS – National Health Registries (incl. Czech National Cancer Registry). https://www.uzis.cz/index-en.php?pg=nhis--national-health-registries
3. Czech Statistical Office (CZSO) – Employees and Wages portal. https://csu.gov.cz/employees-and-wages
4. SÚKL – List of reimbursed medicinal products (official portal). https://sukl.gov.cz/en/about-us/reviews-and-lists/list-of-reimbursed-medicinal-products/
5. Eurostat – Health care expenditure by financing scheme (SHA 2011). DOI: 10.2908/hlth_sha11_hf ; dataset page: https://ec.europa.eu/eurostat/databrowser/view/HLTH_SHA11_HF/default/table
6. OECD – Health at a Glance 2023 (indicator compendium). https://www.oecd.org/en/publications/2023/11/health-at-a-glance-2023_e04f8239.html
7. IARC/WHO – Cancer Incidence in Five Continents, Volume XI (2008–2012). https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Scientific-Publications/Cancer-Incidence-In-Five-Continents%C2%A0Volume-XI-2021
8. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol.2020;95(5):548–567. DOI: 10.1002/ajh.25791 ; PubMed: https://pubmed.ncbi.nlm.nih.gov/32212178/
9. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364(11):1046–1060. DOI: 10.1056/NEJMra1011442 ; article: https://www.nejm.org/doi/full/10.1056/NEJMra1011442
10. SVOD – Open data section (exportable oncology datasets). https://www.svod.cz/en/data/open-data/
11. LINKOS – Cancer epidemiology and cancer registries in the Czech Republic (English summary). https://www.linkos.cz/english-summary/national-cancer-control-programme/cancer-epidemiology-and-cancer-registries-in-the-czech-republic/ linkos.cz
12. IHME – GBD 2021 Disability Weights (download & documentation). https://ghdx.healthdata.org/record/ihme-data/gbd-2021-disability-weights
13. WHO – Methods and data sources for GHE/GBD YLD & disability weights (GHE 2021, methods report). https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/ghe2021_daly_methods.pdf
14. Petrucci MT, Calabrese E, Levi A, et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori. 2013;99(4):e193–e202. DOI: 10.1177/030089161309900434 ; PubMed: https://pubmed.ncbi.nlm.nih.gov/24326862/
15. Martínez-López J, et al. Real-world treatment patterns, healthcare resource use and disease burden in multiple myeloma. Future Oncol. 2023;19(32):2529–2544. DOI: 10.2217/fon-2023-0021 ; article: https://www.tandfonline.com/doi/full/10.2217/fon-2023-0021
16. Garrido-Alejos G, et al. Evolution of pharmacological treatments and associated pharmaceutical expenditure for multiple myeloma in Catalonia's public system. Cancers (Basel). 2023;15(22):5338. DOI: 10.3390/cancers15225338 ; article: https://www.mdpi.com/2072-6694/15/22/5338
17. Partanen A, et al. Evolution of treatment practices and outcomes in multiple myeloma during 2013–2022: Finnish real-world registry study. Acta Oncol. 2024. PDF: https://medicaljournalssweden.se/actaoncologica/article/download/42647/50083?inline=1

Project
HealthCare